Zoya Gluzman
Career history of Zoya Gluzman
Former positions of Zoya Gluzman
| Companies | Position | Start | End |
|---|---|---|---|
VESSL Therapeutics Ltd.
 VESSL Therapeutics Ltd. Medical SpecialtiesHealth Technology VESSL Therapeutics Ltd. develops cell-based therapies for large patient populations. Its solutions include MultiGeneAngio fo Peripheral Artery Disease and MultiGeneGraft for end-stage renal disease. The company was founded in August 2000 by Moshe Y. Flugelman and Basil S. Lewis and is headquartered in Haifa, Israel. | Corporate Officer/Principal | - | - |
GeneGrafts Ltd.
 GeneGrafts Ltd. BiotechnologyHealth Technology GeneGrafts Ltd. develops proprietary technology for modulating excitable tissues. Its technology is used for the treatment of cardiac arrhythmias, Parkinson's disease and other neurological disorders. The company was founded by Yair Feld, Lior Gepstein, Shimon Marom and Meira Melamed Frank in 2003 and is headquartered in Haifa, Israel. | Chief Tech/Sci/R&D Officer | 01/01/2005 | - |
Training of Zoya Gluzman
| Technion-Israel Institute of Technology | Doctorate Degree |
Statistics
International
| Israel | 4 |
Operational
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Masters Business Admin | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
GeneGrafts Ltd.
GeneGrafts Ltd. BiotechnologyHealth Technology GeneGrafts Ltd. develops proprietary technology for modulating excitable tissues. Its technology is used for the treatment of cardiac arrhythmias, Parkinson's disease and other neurological disorders. The company was founded by Yair Feld, Lior Gepstein, Shimon Marom and Meira Melamed Frank in 2003 and is headquartered in Haifa, Israel. | Health Technology |
VESSL Therapeutics Ltd.
VESSL Therapeutics Ltd. Medical SpecialtiesHealth Technology VESSL Therapeutics Ltd. develops cell-based therapies for large patient populations. Its solutions include MultiGeneAngio fo Peripheral Artery Disease and MultiGeneGraft for end-stage renal disease. The company was founded in August 2000 by Moshe Y. Flugelman and Basil S. Lewis and is headquartered in Haifa, Israel. | Health Technology |
- Stock Market
- Insiders
- Zoya Gluzman
- Experience
